MedTrace Logo

Clinical Outcome of Patients With Resistant Hypertension Undergoing Renal Denervation

NCT04722159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-01-25

No results posted yet for this study

Summary

Studies on the impact of RDN on cardiovascular surrogate markers have shown a variety of beneficial effects: RDN is associated with a decrease blood pressure (BP), left ventricular mass (LVM), a reduction in aortic pulse-wave velocity and BP variability as well as an increase in heart rate-recovery. Several of these aspects have been observed independently of office BP response, and might be mediated by a direct modulation of the sympathetic nervous system. Moreover, several independent real - world registries have shown an association of renal denervation and sustained blood pressure reductions of clinically relevant magnitude up to 36 months of follow - up.

Whether the sum of these effects may translate into an improvement of clinical outcomes remains unclear and constitutes the primary subject of proposed registry based study.

Conditions

  • Hypertension, Renal

Interventions

DEVICE

Renal denervation

Catheter-based inhibition of renal sympathetic nerve traffic.

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Bert Andersson · Sahlgrenska University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-05-31
Completion
2021-08-31
FDA Device
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722159 on ClinicalTrials.gov